Prometic and Top Meadows establish joint venture for development of Mad Cow Disease diagnostics
Kym Anthony, newly elected Director of ProMetic Life Sciences Inc. and President of Top Meadow, has agreed to invest through Top Meadow the initial seed investment to bring the joint venture's first ante-mortem veterinary blood-based diagnostic product to market. First Associates Investments Inc. acted as advisor to the parties for the formation of the joint venture and has initiated financing activities to raise additional funds.
Mr. Anthony will act as non-executive Chairman of the new joint venture which will attract additional seasoned executives with specific and complementary expertise in the field of diagnostics and veterinary medicine. Pierre Laurin will act as interim CEO. The joint venture will rely on the unique expertise of PRDT's scientists, namely Dr. Robert Rohwer, a renowned expert on prions affiliated with the University of Maryland, Dr. David Hammond, Chairperson of the Scientific Advisory Committee of PRDT and an Executive Director at the American Red Cross, Dr. Ruben Carbonell, Director of the Kenan Institute for Engineering, Technology & Science at North Carolina State University, and Dr. Peter Edwardson, Project Director, PRDT, who will work closely with scientists, regulatory and government officials.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.